Renovaro Biosciences Statistics
Total Valuation
RENB has a market cap or net worth of $308.89 million. The enterprise value is $314.96 million.
| Market Cap | 308.89M |
| Enterprise Value | 314.96M |
Important Dates
The next estimated earnings date is Friday, May 10, 2024, after market close.
| Earnings Date | May 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RENB has 143.67 million shares outstanding. The number of shares has increased by 18.63% in one year.
| Shares Outstanding | 143.67M |
| Shares Change (YoY) | +18.63% |
| Shares Change (QoQ) | +2.13% |
| Owned by Insiders (%) | 26.23% |
| Owned by Institutions (%) | 1.81% |
| Float | 102.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 7.09 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.18, with a Debt / Equity ratio of 0.17.
| Current Ratio | 0.18 |
| Quick Ratio | n/a |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -47.24 |
Financial Efficiency
Return on equity (ROE) is -81.30% and return on invested capital (ROIC) is -78.75%.
| Return on Equity (ROE) | -81.30% |
| Return on Assets (ROA) | -65.30% |
| Return on Capital (ROIC) | -78.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.44M |
| Employee Count | 12 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +91.96% in the last 52 weeks. The beta is 0.30, so RENB's price volatility has been lower than the market average.
| Beta (1Y) | 0.30 |
| 52-Week Price Change | +91.96% |
| 50-Day Moving Average | 2.63 |
| 200-Day Moving Average | 2.90 |
| Relative Strength Index (RSI) | 35.88 |
| Average Volume (30 Days) | 311,588 |
Short Selling Information
The latest short interest is 2.32 million, so 1.62% of the outstanding shares have been sold short.
| Short Interest | 2.32M |
| Short Previous Month | 1.22M |
| Short % of Shares Out | 1.62% |
| Short % of Float | 2.28% |
| Short Ratio (days to cover) | 5.12 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -40.15M |
| Pretax Income | -41.23M |
| Net Income | -41.23M |
| EBITDA | -40.26M |
| EBIT | -40.38M |
| Earnings Per Share (EPS) | -$0.70 |
Balance Sheet
The company has $1.32 million in cash and $7.39 million in debt, giving a net cash position of -$6.07 million or -$0.04 per share.
| Cash & Cash Equivalents | 1.32M |
| Total Debt | 7.39M |
| Net Cash | -6.07M |
| Net Cash Per Share | -$0.04 |
| Equity / Book Value | 43.60M |
| Book Value Per Share | 0.30 |
| Working Capital | -11.36M |
Cash Flow
In the last 12 months, operating cash flow was -$11.49 million and capital expenditures -$47,725, giving a free cash flow of -$11.54 million.
| Operating Cash Flow | -11.49M |
| Capital Expenditures | -47,725 |
| Free Cash Flow | -11.54M |
| FCF Per Share | -$0.18 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RENB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.63% |
| Shareholder Yield | -18.63% |
| Earnings Yield | -13.35% |
| FCF Yield | -3.74% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |